Trial Profile
An Open-label Study Assessing Long-term Safety of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Hyperhidrosis
- Focus Adverse reactions; Registrational
- Acronyms ARIDO
- Sponsors Journey Medical Corporation
- 20 May 2019 Results assessing glycopyrronium tosylate safety and descriptive efficacy published in the American Journal of Clinical Dermatology
- 01 Mar 2019 According to a Dermira media release, results of post hoc analysis were presented at the Annual Meeting of the American Academy of Dermatology (AAD) 2019.
- 01 Mar 2019 Results of post hoc analysis from the study presented in a Dermira media release.